Barclays lowered the firm’s price target on Surgery Partners (SGRY) to $18 from $24 and keeps an Equal Weight rating on the shares. The firm says employer-sponsored insurance coverage looks under pressure but will be “potentially masked” by positive Affordable Care Act trends benefiting hospitals.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Surgery Partners price target lowered to $22 from $28 at Mizuho
- Surgery Partners price target lowered to $29 from $34 at UBS
- Surgery Partners Appoints New COO and President
- Strategic Growth and Portfolio Optimization Drive Buy Rating for Surgery Partners
- Surgery Partners price target lowered to $31 from $35 at RBC Capital